INTRODUCTION
Psoriasis is a common chronic inflammatory disease with a prevalence of 1.5-2.8%
worldwide [1, 2] . Around 6-30% of patients with psoriasis also have psoriatic arthritis [3] [4] [5] .
Psoriasis is a lifelong disease thus leading to considerable burden and expenses [1, 6] . When assessing the health economic consequences of a disease, the perspective of patients is considered important [1, 7] . Psoriasis results in expenses to patients from many cost sources mainly because of medications, topical emollients and balneotherapy [8] [9] [10] [11] [12] . Some psoriasis treatments (mainly phototherapy) are given in hospitals, usually in as a course of treatment, so considerable time and traveling costs can be expected [7, 11, 13] . Studies have estimated that patients have to spend a lot of time each day in home care of psoriasis, but the results have wide variations [11, 12] . Psoriasis also increases the need for cleaning and laundry, and increases the need for assistance at home [11] .
Psoriasis has no known curative treatment; therapy aims to reduce symptoms and gain quality of life. Topical steroids and vitamin D analogs are shown to be the most commonly used treatment method [5] . Phototherapy and/ or systemic medications are combined if necessary [5] . Countries have varying social/ private insurance systems, thus the costs of medications for the patients varies.
The aim of this study was to evaluate the multidimensional economic burden of psoriasis to patients.
MATERIALS AND METHODS

Patient Sample
The sample was based on patients who had They were all diagnosed with moderate to severe psoriasis or psoriatic arthritis. The patient sample is described in detail by Mattila et al. [14] . In the Finnish healthcare system patients with mild psoriasis are treated in primary health care settings and only moderate to severe cases are referred to tertiary level hospitals for further treatment.
In practice, all psoriatic arthritis patients in this study sample also had skin symptoms, which had been the reason for visiting a dermatological clinic.
Ethical Consideration
The ethical committee of The Hospital District of Southwest Finland approved the study. The patients received a written description of the sampling procedure and study purpose, as well as the planned use and storage of the information they were to provide. This was followed by a description of the subject's rights according to the Helsinki declaration. All procedures followed Written informed consent was obtained from all patients for use of their medical records being included in the study.
Questionnaire
The questionnaire collected socio-demographic background information (e.g., sex, age, home municipality, number of persons living in the same household, income level and disease duration).
To evaluate the use of different medical services and associated out-of-pocket expenses and time spent, the subjects were asked the number of visits they had made to a private or occupational health care provider, to a tertiary level hospital and to a health center because of psoriasis during the study period of 1 year. The visits to doctors' office and nurse in each health care facility were recorded separately. The time spent, in hours per year, was recorded for each health service provider. The subjects were asked to evaluate the out-of-pocket expenses associated with the different health care
providers. The subjects were also asked to estimate the distances to each health care provider in kilometers from their home.
The subjects were asked to report how many minutes per week they currently spend on caring for their skin, cleaning and laundry, and to estimate the time in minutes per week they would have spent in a hypothetical situation if they did not have psoriasis. Skin care, cleaning and laundry time caused by psoriasis was defined as the difference between estimated time spent in skin care, cleaning and laundry with and without psoriasis.
The subjects were asked if they received any assistance with running errands or household chores because of psoriasis and respective costs (in euro per month).
Time Cost
All cost estimates were computed to hours per year. To estimate the monetary value of the burden from the time consumed for household chores, running errands, for skin care and treatment-related time, the Human Capital Approach (HCA) was used. The value of an hour was based on the level of total family income per persons in the household. The monthly income levels were computed to an hour. The same formula was applied to retired and unemployed respondents.
Clinical Data
Clinical information was collected from the medical records for the time period that was covered in the questionnaire data. Outpatient and phototherapy visits and the days hospitalized were collected from the hospital records. products (e.g., emollients) purchased during the study period for the patients who had given consent. This reimbursement policy applies to all medications, irrespective of who has prescribed them. All purchase data included the cost for the patient and the amount reimbursed as well as the type of medication purchased. If the out-of-pocket expenses for medicine and emollients exceed 672 euro during a calendar year, the exceeding reimbursement was at a rate of 100% so the cost maximum was set to 672 euro.
Travel Costs and Time
Travel costs were estimated using the distances from patients' home to different health care providers and the number of visits in each destination. If the distance to a service provider was less than 12.5 km, a typical regional bus fee of 2.5 euro was applied. For distances beyond 12.5 km, 0.20 euro/km derived from FSII reimbursement rate for traveling cost was used for costs calculations.
The time patients spent on traveling to different health service providers was estimated using the distance to the service provider from their home municipality and the number of visits to each provider; register data were used for TUH visits. An approximation of 1.5 min per kilometer was used with an additional fixed amount of 5 min representing the time needed to park the car or walk from the bus stop to the hospital. In the few cases where the estimated travel time to a service provider and back home exceeded 2.5 h, it was capped at 2.5 h.
Visit Time
The time spent at different health care providers was solicited in the questionnaire and used to evaluate the costs of the time needed for visits.
Due to the significance of time needed for phototherapy, a separate survey was conducted, where the actual time needed by 40 patients with psoriasis attending phototherapy at TUH was observed. UVB and bath-PUVA therapies were separately recorded. UVB visits took on average 16 min and bath-PUVA took 43 min.
Other forms of PUVA treatment than bath-PUVA were not used. These times were then used for time-cost calculations of phototherapy.
Visiting Charges
The provider.
Statistical Analyses
The statistical evaluation of the data was based on Student's t test for means and Chi-square test for proportions. Linear regression models were used to study how different background factors affected the variation in treatment cost estimates. In the analyses all patients with missing information in any of the analyzed variables were excluded. All analyses were based on all patients irrespective of the diagnosis of psoriasis or psoriatic arthritis.
RESULTS
The patients had relatively low psoriasis severity ( Table 1 ). The total costs to patients were higher for those receiving traditional systemic medications than not receiving systemic medications (Table 2 ). Medicine costs, skin care cost and costs of assistance for household chores comprised most of the differences ( Medications and phototherapy formed 18% of the total economic burden for a patient. A majority of the total visit costs incurred by patients were from visiting TUH and only a small proportion from visiting all primary health care providers (Table 4) . Patients with psoriatic arthritis received more phototherapy and had more visits, thus had higher visiting costs than patients with psoriasis ( 
DISCUSSION
There is little information concerning the costs of psoriasis incurred by patients. In this study, the co-payments for visits to hospital and for medications and emollients comprised only a minority of the total costs for a patient, while Table 3 The composition of phototherapy costs (euro) (standard deviation in parenthesis) (n = 83) travel costs and lost time were estimated to contribute the majority of the costs to patients. In a recent study in Spain [15] , the relationship of travel costs and time costs were similar from the patients' perspective. Phototherapy has been estimated to be costly for patients [2, 7, 8, 11] . In this study, biologic therapy and phototherapy had almost equal costs to patients. In studies in the US, lower out-of-pocket costs for patients have been estimated to have led to favoring biologic therapies over phototherapy [16, 17] . This can lead to higher total costs for the society of psoriasis treatment as phototherapy has been estimated to be the most cost-efficient, or one of the most cost-efficient, treatment methods of psoriasis [18] [19] [20] . However, travel costs and travel time costs are rarely included in cost estimations of psoriasis treatments [16, [19] [20] [21] , which may have led to underestimation of the actual costs of phototherapy. The current sample included all patients visiting the clinic during 1 year. Thus, all types of phototherapy patients can be assumed to be represented, those in remission as well as those in active treatment; and the costs were based on the actual number of visits during the whole year. In this study the indirect costs were estimated to comprise the majority of costs of phototherapy for the patients. Earlier studies have estimated that travel costs account for around two-thirds of the total costs of phototherapy [22] . Time lost because of phototherapy has been estimated to be around 110 min/treatment session [22] or take 33 h per year [11] . It has been reported that, from the perspective of patients, travel distance plays a major role in treatment selection [23] . Loss of time, whether working or leisure time, has value to the patients, irrespective of the lost earnings.
Cost items Cost
In this study, the aim was to analyze the burden of the disease to a patient, not to employers, or the society as a whole. Thus, possible productivity losses from absenteeism or presenteeism were not included.
A recent study suggests that patients living further away from UV-treatment facility have lower dermatology life quality index (DLQI) and suffer from lack of treatment [23] . The current study indicated that patients living further away from tertiary level hospital receive less phototherapy, which may be due, in part, to the decisions made by patients and not just the decisions made by treatment providers. Studies are required to determine if patients living further away from service provider suffer from under treatment. Home phototherapy is rarely used in our study area In some earlier studies [16] , medication costs were estimated using average prices and average weekly doses. This can be a source for potential overestimates of medication costs as a considerable proportion of psoriasis patients do not necessarily use the medications as prescribed [24] . In the study all medicine and emollient costs were based on reimbursement data of all purchases, irrespective of who had prescribed the medications, which can be expected to produce more reliable medication cost estimates. Countries have varying social security systems and reimbursement rates so direct comparison between studies has been considered problematic [7, 12, 25] . For example, in this study setting, the cut-off level for complete medicine cost reimbursement was based on national policy. Thus, the medication costs to patients in this study may not be directly generalizable to other countries.
As in this study, earlier studies [8, 19] The primary provider of treatment for patients with psoriasis varies between countries [28] . In most studies patients have been treated mainly by dermatologists [28, 29] , as in this study. In Finland, patients with well managed and mild psoriasis are usually treated by general practitioners, with referral to a tertiary level dermatological clinic when exacerbations occur. This may have led to selection bias in the sample as only patients from the dermatological clinic were included.
The current study corroborates earlier studies [8, 11, 13, 30] 
CONCLUSION
Information concerning the costs of psoriasis from the perspective of patients is still limited.
In this study, the co-payments for visits to hospital and for treatments were estimated to play a minor role in the total costs for a patient, with travel costs and lost time contributing most of the costs. These indirect costs of treatments should not be omitted in future studies as they can be a significant factor when choosing treatments, especially for the patients with psoriasis.
ACKNOWLEDGMENTS
All named authors meet the ICMJE criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.
This study and associated article processing charges were supported by grants from the Hospital District of Southwest Finland. 
